HD-OPM Archive
Topics › GLP-1 drugs (semaglutide, tirzepatide)

New Cell Reports Medicine paper: GLP-1 drugs do not cause disproportionate muscle loss

Louis Nervegna · Apr 26, 2026 · ♥ 7 reactions · 2 comments · original Facebook post
GLP-1 drugs (semaglutide, tirzepatide)Weight, visceral & liver fatExercise & fitness
AI summary & key facts

Louis shares a summary stressing lean body mass includes liver and other tissues, and GLP-1 drugs preserved strength and function.

Yet another study showing that GLP1 agonists do not cause muscle loss any worse than normal calorie restriction diets.

#glp1HD

Research cited

The Real Takeaway on GLP-1 Weight Loss and “Muscle Loss”

The new paper in Cell Reports Medicine sends a very clear message:
GLP-1 drugs (semaglutide, tirzepatide, etc.) do NOT cause a disproportionate loss of muscle mass or function.

They primarily cause:
✅ fat loss
✅ liver mass reduction
✅ improved body composition
✅ preserved strength
✅ better mobility and physical performance

The Most Important Concept
The biggest misconception is this:
Lean Body Mass ≠ Skeletal Muscle
Many people panic because studies show a reduction in lean body mass (LBM).

But LBM includes: liver, heart, bones, body water, other lean tissues —not just muscle.

In this study, the reduction in liver mass often exceeded the reduction in skeletal muscle mass, especially in obese mice treated with GLP-1 therapies.
That completely changes the interpretation.

In Humans
In the clinical trial:

Despite this:
✔ quadriceps strength was maintained
✔ handgrip strength was maintained
✔ no meaningful functional decline was observed

This is the key clinical point.
Not “Did LBM decrease?”
but:
“Did function worsen?”
And the answer appears to be:
No.

In Mice
With semaglutide:

In simple terms:

= better mobility

This is often missed.

The Provocative Truth
We are probably not “losing muscle.”
We are losing:
👉 fat
👉 fatty liver
👉 metabolically useless excess tissue
…and people are incorrectly calling that:
“sarcopenia.”
That is a major conceptual mistake.

Clinically
The real question should never be:
“Is lean mass going down?”
It should be:
“Is the patient becoming weaker?”

This paper strongly suggests: No—often the opposite.

Patients may actually move better, function better, and feel better despite a mild reduction in absolute muscle size.

Bottom Line
GLP-1 medicine is not creating a sarcopenia epidemic.
It is exposing how badly we misunderstand body composition.
And perhaps the real problem is not muscle loss—
but our obsession with the wrong metric.

No photo description available.
#muscle#liver#weightloss#semaglutide#mice#sarcopenia#calorierestriction#fattyliver
← newer: 1,000 more daily steps tied to 15% lower all-cause death; 50older: Aspirin halved colorectal cancer in Lynch syndrome in a 861- →